Clinical Trials Logo

Platinum Responsive Malignancies clinical trials

View clinical trials related to Platinum Responsive Malignancies.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01110226 Terminated - Clinical trials for Platinum Responsive Malignancies

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies

0805GCC
Start date: April 27, 2010
Phase: Phase 1
Study type: Interventional

This is a Phase I Clinical Trial. Phase I studies are designed to determine the amount of investigational drugs that can be safely tolerated and to define the side effects that limit the dose. The drug administered in this study is KML-001. It is a highly soluble, orally available arsenic agent. It is currently being tested to determine its effects on telomerase activity. In other words, the purpose of this research study is to find the highest dose of KML001, that can be given without causing severe side effects when it is combined with a standard, commercially available anti-cancer drug called cisplatin.